SCHEMBL19252528

SCHEMBL19252528

C#CCNC(=O)c1ccc(C(C)(C)C)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.61
CA2 P00918 2/20 0.61
CA12 O43570 1/20 0.61
CA9 Q16790 1/20 0.61
CA14 Q9ULX7 1/20 0.61
RAB9A P51151 4/20 0.57
NPC1 O15118 3/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
LMNA P02545 1/20 0.57
TP53 P04637 1/20 0.57
HPGD P15428 1/20 0.57
NFKB1 P19838 1/20 0.57
MAPK1 P28482 1/20 0.57
NFKB2 Q00653 1/20 0.57
RELA Q04206 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
HDAC1 Q13547 1/20 0.56
EPHX2 P34913 12/20 0.55
NR1H4 Q96RI1 9/20 0.55
HDAC3 O15379 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18704415 0.84 CA12 (0.59) CA1CA2CA12CA9CA14
SCHEMBL21652280 0.82 EPHX2 (0.61) RAB9ANPC1L3MBTL1LMNATP53
SCHEMBL18364959 0.81 CA12 (0.65) CA1CA2CA12CA9CA14
SCHEMBL14297345 0.81 CA12 (0.65) CA1CA2CA12CA9CA14
SCHEMBL28856783 0.80 CA2 (0.68) CA1CA2CA12CA9CA14
SCHEMBL6646101 0.80 CA1 (0.63) CA1CA2CA12CA9CA14
SCHEMBL2601677 0.80 CA12 (0.63) CA1CA2CA12CA9CA14
SCHEMBL2605517 0.80 CA12 (0.63) CA1CA2CA12CA9CA14
SCHEMBL7210123 0.80 CA12 (0.68) CA1CA2CA12CA9CA14
SCHEMBL17670827 0.80 CA1 (0.63) CA1CA2CA12CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119161324-A Methods and compounds for restoring mutant p53 function 皮姆维制药公司 2024-12-20 CN disclosed
US-20220213062-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2022-07-07 US disclosed
CN-112538058-B Preparation method of oxazole-containing cyclic sulfone compound 温州大学新材料与产业技术研究院 2022-05-27 CN disclosed
US-11339141-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2022-05-24 US disclosed
CN-112538058-A Preparation method of oxazole-containing cyclic sulfone compound 温州大学新材料与产业技术研究院 2021-03-23 CN disclosed
US-20210002252-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2021-01-07 US disclosed
US-10640485-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2020-05-05 US disclosed
US-20190119249-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2019-04-25 US disclosed
EP-3416638-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV Pharmaceuticals, Inc. (US) 2018-12-26 EP disclosed
US-10138219-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS (US) 2018-11-27 US disclosed
WO-2017143291-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2017-08-24 WO disclosed
US-20170240525-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2017-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170240525-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS CA1 2828/4885CA2 3501/4885CA12 3754/4885
US-11339141-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, KRAS CA1 2828/4885CA2 3501/4885CA12 3754/4885
US-20220213062-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS CA1 2828/4885CA2 3501/4885CA12 3754/4885
US-20190119249-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS CA1 2828/4885CA2 3501/4885CA12 3754/4885
US-10640485-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, KRAS CA1 2828/4885CA2 3501/4885CA12 3754/4885
US-20210002252-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS CA1 2828/4885CA2 3501/4885CA12 3754/4885
US-10138219-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, KRAS CA1 2828/4885CA2 3501/4885CA12 3754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.